A letter in response to "Cancer stem cells: emerging actors in both basic and clinical cancer research" Turk J Biol (2014) 38: ©TÜBITAK - doi:10.3906/biy-1406-93 Cancer stem cells (CSCs): targets and strategies for intervention

This letter to the editor highlights the important aspects of cancer stem cells and provides a deeper insight into the origin and characterization of these cells as well as the mechanisms contributing to drug resistance and relapse. The two currently available models (CSC and the clonal evolution model) need not be mutually exclusive to explain the origin of CSCs. The identification of CSCs (based on surface markers, drug efflux, enzyme activity, and signal transduction molecules and proteins involved in EMT processes) can help in discriminating these cells from other cell types. Moreover, CSCs prefer a hypoxic environment. This microenvironmental cue can trigger certain metabolic alterations that can orchestrate a rewiring of the epigenome. Consequently, changes in transcription factors and signaling molecules can contribute to the plasticity/inter-convertibility of the CSCs and non-CSC cellular states. Hence, an improved understanding of the mechanisms involved also provides opportunities for pharmacological manipulations. This letter also underscores the presence of precancerous stem cells as well as very small embryonic-like stem cells (VSELs) (both considered to be precursors of CSCs). These reports warrant a thorough reanalysis of the source of CSCs (lineage tracing studies), subsequent to the development of better targeted intervention approaches.

Anahtar Kelimeler:

Cancer stem cells, precancerous stem cells, very small embryonic-like stem cells, pharmacological strategies, drug resistance

A letter in response to "Cancer stem cells: emerging actors in both basic and clinical cancer research" Turk J Biol (2014) 38: ©TÜBITAK - doi:10.3906/biy-1406-93 Cancer stem cells (CSCs): targets and strategies for intervention

Keywords:

Cancer stem cells, precancerous stem cells, very small embryonic-like stem cells, pharmacological strategies, drug resistance,

PDF

___

Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, Piccirillo S, Vescovi AL, DiMeco F, Olivi A et al. (2007). Cyclopamine-me- diated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524–2533.
Bedard PL, Cardoso F, Piccart-Gebhart MJ (2009). Stemming resis- tance to HER-2 targeted therapy. J Mammary Gland Biol Neo- plasia 14: 55–66.
Cheli Y, Bonnazi VF, Jacquel A, Allegra M, De Donatis GM, Baha- doran P, Bertolotto C, Ballotti R (2014). CD271 is an imperfect marker for melanoma initiating cells. Oncotarget 5: 5272–5283.
Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y et al. (2007). Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS One 2: 1–16.
Gossett DR, Weaver WM, Mach AJ, Hur SC, Tse HT, Lee W, Amini H, Di Carlo D (2010). Label-free cell separation and sorting in microfluidic systems. Anal Bioanal Chem 397: 3249–3267.
Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next gen- eration. Cell 144: 646–674.
Hartomo TB, Van Huyen Pham T, Yamamoto N, Hirase S, Hasegawa D, Kosaka Y,Matsuo M, Hayakawa A, Takeshima Y, Iijima K et al. (2014). Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma. Int J Oncol: doi: 10.3892/ijo.2014.2801.
Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, Brown AM, Ng K, Ma J, Wienholds E, Dunant C et al. (2013).Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339: 543–548.
Kühnle M, Egger M, Müller C, Mahringer A, Bernhardt G, Fricker G, König B, Buschauer A (2009). Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p- glycoprotein (ABCB1) modulator tariquidar. J Med Chem 52: 1190–1197. doi: 10.1021/jm8013822.
Lee E, Hong Y, Choi J, Haam S, Suh JS, Huh YM, Yang J (2012). Highly selective CD44-specific gold nanorods for photothermal abla- tion of tumorigenic subpopulations generated in MCF7 mam- mospheres. Nanotechnology 23: 465101 doi:10.1088/0957- 4484/23/46/465101.
Lee IC,Chang JF (2014). Label-free selection and enrichment of liver cancer stem cells by surface niches build up with polyelec- trolyte multilayer films. Colloids Surf B Biointerfaces 125C: 120–126.
Liu HG, Chen C, Yang H, Pan YF, Zhang XH (2011). Cancer stem cell subsets and their relationships. J Transl Med 9: 1–9.
Ma I, Allan AL (2011). The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292–306.
Menendez JA, Alarcón T (2014). Metabostemness: a new cancer hall- mark. Front Oncol 4: 1–21.
Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin AT (2013). Warburg effect version 2.0: meta- bolic reprogramming of cancer stem cells. Cell Cycle 12: 1166– 1179.
Mishra DK, Scott KL, Wardwell-Ozgo JM, Thrall MJ, Kim MP (2015). Circulating tumor cells from 4D model have less integ- rin beta 4 expression. J Surg Res 193: 745–753.
Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS (2012). Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs 21: 1247–1266.
Ratajczak MZ, Shin DM, Liu R, Marlicz W, Tarnowski M, Ratajczak J, Kucia M (2010). Epiblast/germ line hypothesis of cancer de- velopment revisited: lesson from the presence of Oct-4+ cells in adult tissues. Stem Cell Rev 6: 307–316.
Ratajczak MZ, Zuba-Surma EK, Machalinski B, Ratajczak J, Kucia M (2008). Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. Stem Cell Rev 4: 89–99.
Suresh PK (2015). Mechanisms of pluripotency & epigenetic reprogramming in primordial germ cells (PGCs) - lessons for the conversion of other cell types into the stem cell lineage. Turk J Biol 39: 187–193.
Suresh PK, Nathawat L (2014). Role of cadherin switching in EMT and prostate cancer metastasis – a topic revisited. International Journal of Pharmacy and Pharmaceutical Sciences 6: 97–102.
Uckermann O, Galli R, Anger M, Herold-Mende C, Koch E, Schack- ert G, Steiner G, Kirsch M (2014). Label-free identification of the glioma stem-like cell fraction using Fourier-transform in- frared spectroscopy. Int J Radiat Biol 90: 710–717.
Vishnoi M, Mishra DK, Thrall MJ, Kurie JM, Kim MP (2014). Circulating tumor cells from a 4-dimensional lung cancer model are resistant to cisplatin. J Thorac Cardiovasc Surg 148: 1056–1063.
Weller P, Nel I, Hassenkamp P, Gauler T, Schlueter A, Lang S, Dount- sop P, Hoffmann AC, Lehnerdt G (2014). Detection of circulat- ing tumor cell subpopulations in patients with head and neck squamous cell carcinoma (HNSCC). PLoS One 9: e113706. doi: 10.1371/journal.pone.0113706. eCollection 2014.
Wu T, Harder BG, Wong PK, Lang JE, Zhang DD (2014). Oxidative stress, mammospheres, and Nrf2-new implication for breast cancer therapy? Mol Carcinog doi: 10.1002/mc.22202.
Zuba-Surma EK, Kucia M, Wu W, Klich I, Lillard JW Jr, Ratajczak J, Ratajczak MZ (2008). Very small embryonic-like stem cells are present in adult murine organs: ImageStream-based morphological analysis and distribution studies. Cytometry A 73A: 1116–1127.